BT-50 Main target antigen for atypical pANCA for use in diagnostic tests

Scientists at the University of Bonn, Germany, have identified the main target antigen for the atypical antineutrophil

cytoplasmic antibodies pANCA in autoimmune liver disorders and chronic inflammatory bowel diseases. BT-50 can be produced by recombinant means and used for the quantification of atypical pANCA in serum probes.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Researcher Claudia Schmidt analyzing Arctic fjord water samples affected by glacial melt.

Breaking the Ice: Glacier Melting Alters Arctic Fjord Ecosystems

The regions of the Arctic are particularly vulnerable to climate change. However, there is a lack of comprehensive scientific information about the environmental changes there. Researchers from the Helmholtz Center…

Genetic analysis reveals new depression risk factors across diverse populations

Global Genetic Insights into Depression Across Ethnicities

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity. The world’s…

Participants engaging in the Healthy Lifestyle Program to manage chronic low back pain.

Back to Basics: Healthy Lifestyle Reduces Chronic Back Pain

Low back pain is a leading cause of disability worldwide with many treatments, such as medication, often failing to provide lasting relief. Researchers from the University of Sydney’s Centre for Rural…